Regina Trollmann

Head of Pediatric Neurology/Prof. Dr. med

Friedrich-Alexander Universität Erlangen-Nürnberg
Country flagGermany
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Background: Risdiplam is approved for the treatment of 5q-SMA from birth for all types and stages. However, broader data for adults are scarce. We aimed to assess safety and efficacy of risdiplam in adults with SMA. Methods: This is an observational cohort study at 38 academic clinical sites in German-speaking countries. Patients with genetically confirmed 5q-SMA (age 16–69 years) were included and received risdiplam treatment for a minimum treatment time of 6 months to a follow-up of up to 30 months. Primary outcome was the change in the total Revised Upper Limb Module (RULM) score, assessed at baseline to months 4-6, 12-14 and 28-30, and based on pre–post comparisons. This study is registered with the German Clinical Trials Register (DRKS00012699). Findings: Risdiplam showed significant motor improvement across a wide phenotypic spectrum of adult SMA patients regardless of age, SMN2 copy number, and functional status. 74% of patients improved or stabilized at 30 months in RULM; patients do not only deteriorate less rapidly but continue to stabilize or even improve at later time points. Maximum RULM improvement was 1.37 points in SMA3 patients at month 12/14, while at all other timepoints, both in SMA1 and SMA2 patients, mean RULM improvement was below 1 and at all time points below the CMC of 2. We did not detect a correlation between RULM improvement and age, sex or body weight, nor significant changes in HFMSE and 6MWT. No new safety findings were detected. Interpretation: Our study provides real-world data from the multinational SMArtCARE registry on efficacy and safety of risdiplam in 194 adult ambulatory and non-ambulatory SMA patients over 4-30 months of treatment. Funding: Financial support for the SMArtCARE registry is provided by Biogen, Novartis and Roche. Declaration of Interest: BS, BK, CB, CS, CR, EH, GSa, GS, MS, OS and VP declare no conflicts of interest. AB received honoraria for advisory board attendance, speaker’s fees from Biogen, Novartis, Roche, Italpharmaco, SantheraMT received honoraria for advisory board attendance, speaker’s fees and research funding from Alexion, Amicus, AstraZeneca, Sanofi Genzyme, Takeda, outside of the present work. AE received speakers´ fees and honoraria for advisory board attendance from Novartis, Biogen, Roche AH received funding for Travel and/or Speaker Honoraria from Roche, Biogen, Novartis, PTC Therapeutics, Santhera, Biomarin, and Takeda. He received research support from Roche, Sanofi, Takeda, Biomarin. AR received speaker fees from Amylyx Pharmaceuticals, ROCHE, Argenx, UCB Pharma, Alexion Pharma, Zambon and ITF Pharma, travel support for congress from Zambon and Johnson&Johnson and served on advisory boards for Biogen and Argenx, outside of the submitted work. ASN reports Adborad Meetings with Roche, Biogen, Novartis and Santhera Pharmaceuticals. CN received honoraria for advisory board attendance, speaker’s fees and travel grants from Biogen USA, Biogen Switzerland, Roche, Sanofi Genezyme, Mitsubishi Tanabe, Alexion, Argenx, Amicus, Johnson & Johnson, Amgen, Jannsen DH received honoraria for advisory board attendance from Novartis. DZ received honoraria for advisory board attendance from Biogen and Amicus, for consultancy from Novartis, and travel support for conference attendance from Zambon, outside of the present work. FK received speaker honoraria from Roche, Amicus, Alexion, Sanofi; travel support for conference attendance from Roche, ITF Pharma and Amicus, and served on advisory boards for Amicus, Roche, and Abcuro. GMzH received compensation for serving on scientific advisory boards (JnJ, Immunovant), speaker honoraria (Amgen, Argenx) and scientific project funding (Biogen). GW has received honoraria for advisory board attendance, speaker’s fees from Roche, Novartis, Alnylam and AstraZeneca outside of the present work. HC received honoraria for advisory board attendance, speaker’s f

Year:

2026

Objectives Activin A, a multifunctional growth and differentiation factor and neuroglobin (Ngb), an oxygen‐dependent heme protein, have been proposed as novel oxygen‐dependent neuroprotectants. Both these endogenous cytoprotective factors are partially controlled by hypoxia‐inducible transcription factors (HIFs) and are strongly upregulated in various forms of acute brain injury, including traumatic, hypoxic and ischaemic lesions. Considering their potential role as biomarkers of neonatal brain injury, we investigated the regulatory effects of seizure‐induced excitotoxicity and acute hypoxia on the activin A and Ngb systems in the developing mouse brain. Methods We analysed the effects of acute pilocarpine‐induced seizures in the brains of neonatal C57BL/6 WT mice (P10) on the age –and region‐specific mRNA (real‐rime‐PCR) and protein expression (IHC) of Ngb and activin A (and activin A's receptors—activin A receptor Type IB, ActRIB; activin A receptor type IIA, ActRIIA; and activin A receptor Type IIB, ActRIIB) after 0–72 h of regeneration. Using the established mouse model of acute neonatal hypoxic brain injury, the same analyses were performed on the brains of another group of mouse pups (P7) subjected to acute hypoxia (FiO 2 8% for 6 h) and the prolyl hydroxylase inhibitor (PHI) FG‐4497, which stabilizes cerebral HIF accumulation. Results (Mean ± SEM) Seizures induced significant changes in the regulation of both Ngb and activin A. Cerebral Ngb mRNA expression increased over time in response to acute seizure activity (Ngb mRNA ratio: 6 h: 4.75 ± 0.79, 72 h: 10.53 ± 1.71; vs. controls 6 h: 6.23 ± 1.15, 72 h: 8.12 ± 0.56, p < 0.01), exceeding the expected age‐related increase. Activin A mRNA expression significantly decreased within 6 h of regeneration in response to seizures compared to controls ( p < 0.01), while mRNA levels of specific receptors were unaffected. In response to acute hypoxia and FG‐4497, a marked upregulation of cerebral Ngb mRNA concentrations was observed compared to controls (Ngb mRNA ratio: 1.99 ± 0.73 vs. 0.82 ± 0.09, p < 0.05). Contrary to the findings in the seizure‐exposed brains, a significant upregulation of activin A, ActRIB and ActRIIB was detected in response to hypoxia and high‐dose FG‐4497 compared to controls. Conclusions The present results demonstrate the differential regulation of Ngb and activin A in relation to time and type of injury and indicate their potential roles as biomarkers of excitotoxic and hypoxic injury in the developing brain.

Year:

2025

Objective: Autoimmune psychosis (AP), defined as an isolated schizophreniform psychosis with no or only minimal neurological abnormalities stemming from autoantibody-associated cerebral processes, is a very rare and potentially underdiagnosed disorder in children and adolescents. Methods: This article reports the case of a 13-year-old boy who became acutely ill with a psychotic disorder following a respiratory infection. We describe the diagnosis and course of treatment in detail. Results: Following an extensive interdisciplinary workup, a probable glutamic acid decarboxylase (GAD)-associated AP was diagnosed that ultimately remitted completely with treatment. Conclusions: Autoimmune psychoses remain a relatively uncharted territory for the specialty of child and adolescent psychiatry. Good interdisciplinary cooperation is essential for patients with somewhat atypical psychotic symptoms, both in terms of diagnosis and treatment.

Year:

2025

Background The introduction of newborn screening (NBS) for spinal muscular atrophy (SMA) has increased the early diagnosis of 5q-associated SMA in presymptomatic and symptomatic preterm infants. National and international recommendations for treating preterms and newborns < 38 weeks of gestational age are unavailable. Our retrospective multicentre study aimed to evaluate the postnatal clinical course of preterm infants with 5q-associated SMA diagnosed since the implementation of NBS in Germany in 2021 and to summarize the German experience regarding the decision-making process for available treatment regimens for preterm infants with ≤ 3 survival of motor neuron 2 ( SMN2 ) copies. Results Twelve preterm infants with 5q-associated SMA and a mean gestational age of 34.0 weeks (range: 26.1–36.8) and birth weight of 2022 g (range: 645–3370) were reported from 8/20 German SMA NBS follow-up centers using a pseudonymized questionnaire. Confirmatory diagnosis, including SMN2 copy number, was completed on average on postnatal day 13. All patients had a biallelic deletion of exon 7 or exons 7 and 8 of the survival of motor neuron 1 ( SMN1 ) gene, with SMN2 copy numbers of two in 10 patients and three in two patients. The neonatal course was complicated by respiratory distress due to prematurity ( n = 2), sepsis ( n = 2), and jaundice ( n = 2). At birth, 11 preterm infants (91.6%) were presymptomatic. However, the neurological status of one patient deteriorated at five weeks of age (postconceptional age of 41.8 weeks) prior to the start of treatment. Disease-modifying treatments were initiated in all patients at a mean postconceptional age of 38.8 weeks, with the majority receiving onasemnogene abeparvovec (83.3%, including 2 patients with prior risdiplam bridge therapy). Notably, consensus among participating experts from German neuromuscular centers resulted in 83.3% of patients receiving disease-modifying treatment at term. Conclusions Premature infants with SMA require interdisciplinary care in close collaboration with the neuromuscular center. SMA NBS facilitates early initiation of disease-modifying therapy, ideally during the presymptomatic phase, which significantly influences the prognosis of the newborn.

Year:

2024

Objective The aim of the study was to assess whether children and adolescents with epilepsy are at higher risk of behavioral disturbances when they have concomitant cognitive disturbances. Methods Behavioral scores were generated using the Child Behavior Checklist (CBCL). Cognitive evaluation was applied by using different age appropriate versions of the Wechsler Intelligence Scale. CBCL scores (total, externalizing, internalizing) were compared between patients with and without intellectual disability (IQ score < 70 and ≥70, respectively). Results 144 (10.2 mean age, 6.0–17.9 range) patients were recruited for the study. Patients with mild to moderate intellectual disability (full‐scale intelligence quotient (FSIQ) < 70) were not at higher risk of behavioral disturbances (total CBCL score ≥ 63) than patients without cognitive impairment. The mean total CBCL score was 62.0 ± 10.6 (range 42.0–83.5, 95% CI 57.9–62.0) and 59.3 ± 10.3 (range 38.0–80.0, CI 57.4–61.2) for patients with FSIQ < 70 and ≥70, respectively. There was no correlation between FSIQ and total CBCL scores. These findings were true for all IQ subcategories. Significance Behavioral disturbances among children and adolescents with epilepsy occur despite the presence or absence of intellectual dysfunction with respect to full‐scale IQ.

Year:

2024

This data analysis aimed to systematically analyze a pediatric patient population with a life-limiting disease who were administered cannabinoids. It was a retrospective single-center analysis of patients under supervision of the specialized outpatient pediatric palliative care (SOPPC) team at the Department of Pediatrics and Adolescent Medicine of the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU). Thirty-one patients with a primary diagnosis of neuropediatric, oncologic, metabolic, and cardiologic categories were included. The indications we identified were spasticity, pain, restlessness, anxiety, loss of appetite, epilepsy, and paresis. Certain aspects of quality of life were improved for 20 of 31 patients (64.5%). For nine patients (29%), no improvement was detected. No conclusions could be drawn for two patients (6.5%). Adverse events were reported for six of the thirty-one patients (19.4%). These were graded as mild, including symptoms such as restlessness, nausea, and behavioral issues. We detected no clinically relevant interactions with other medications. We collected fundamental data on the use of cannabinoids by pediatric palliative patients. Cannabinoids are now frequently administered in pediatric palliative care. They seem to be safe to use and should be considered an add-on therapy for other drug regimens.

Year:

2024

Collaborators (17)

Christoph Neuwirth

Deputy Head

Kantonsspital St. Gallen

SWITZERLAND
View details

Wolfgang Löscher

Medical University of Innsbruck

AUSTRIA
View details

Markus Weiler

Prof. Dr

University Hospital Heidelberg

GERMANY
View details

Christoph Kleinschnitz

Head of Department

University Hospital Essen

GERMANY
View details

Omar Keritam

Medical University of Vienna

AUSTRIA
View details

Susanne Petri

Associate Professor

Hannover Medical School

GERMANY
View details

Daniel Zeller

University Hospital Würzburg

GERMANY
View details

Andreas Merkenschlager

Leipzig University

GERMANY
View details

Gerd Meyer zu Horste

Heisenberg-Professor and Attending Neurologist

-

GERMANY
View details

Ingo Borggraefe

-

GERMANY
View details

Marcus Deschauer

-

GERMANY
View details

Ralf A. Husain

Consultant neuropediatrician/ head of Centre of Inborn Errors of Metabolism

University Children's Hospital

GERMANY
View details

Maggie C. Walter

Associate Professor of Neurology

Friedrich-Loeffler-Institut

GERMANY
View details

Matthias Baumann

Medical University of Innsbruck

AUSTRIA
View details

Georges Sam

University Hospital Heidelberg

GERMANY
View details

Hakan Cetin

-

AUSTRIA
View details

Hanns Lochmüller

Senior Scientist

-

CANADA
View details